Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021)

Mesoblast (MESO) posted quarterly Non-Current Deferred Tax Liability of $80.2 million for Q4 2021, little changed year-on-year from $80.1 million in Q4 2020, and little changed on a QoQ basis from $80.2 million in Q3 2021.

Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends

Mesoblast (MESO) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $80.2 million the latest figure, recorded in Q4 2021.

  • Quarterly Non-Current Deferred Tax Liability changed 0.11% year-over-year to $80.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $80.2 million (changed 0.11% YoY) and the FY2021 annual result came in at $80.2 million, up 10881.37% from the prior year.
  • Non-Current Deferred Tax Liability steadied at $80.2 million in Q4 2021 per MESO's latest filing, from $80.2 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for MESO reached as high as $80.2 million in Q3 2021 and fell as low as $730000.0 in Q2 2020.
  • A 5-year average of $45.0 million and a median of $47.8 million in 2017 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability plunged 99.05% — and 2021, when it surged 10881.37%.
  • Year by year, Non-Current Deferred Tax Liability stood at $23.9 million in 2017, then plunged by 30.98% to $16.5 million in 2018, then sank by 58.06% to $6.9 million in 2019, then soared by 1057.43% to $80.1 million in 2020, then gained by 0.11% to $80.2 million in 2021.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $80.2 million, $80.2 million, and $80.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Mesoblast 2.08 Bn 1.95 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2021 80.21 Mn
Dec 31, 2021 80.21 Mn
Sep 30, 2021 80.25 Mn
Sep 30, 2021 80.25 Mn
Jun 30, 2021 80.16 Mn
Jun 30, 2021 80.16 Mn
Mar 31, 2021 80.20 Mn
Mar 31, 2021 80.20 Mn
Dec 31, 2020 80.12 Mn
Dec 31, 2020 80.12 Mn
Sep 30, 2020 79.91 Mn
Sep 30, 2020 79.91 Mn
Jun 30, 2020 730,000.00
Jun 30, 2020 730,000.00
Mar 31, 2020 4.97 Mn
Mar 31, 2020 4.97 Mn
Dec 31, 2019 6.92 Mn
Dec 31, 2019 6.92 Mn
Sep 30, 2019 9.20 Mn
Sep 30, 2019 9.20 Mn